Abstract:Background High-mobility group box 1 (HMGB1) is a multifunctional redox-sensitive protein involved in various intracellular (eg, chromatin remodeling, transcription, autophagy) and extracellular (inflammation, autoimmunity) processes. Regarding its role in cancer development/progression, paradoxical results exist in the literature and it is still unclear whether HMGB1 mainly acts as an oncogene or a tumor suppressor. Methods HMGB1 expression was first assessed in tissue specimens (n=359) of invasive breast, lung and cervical cancer and the two distinct staining patterns detected (nuclear vs cytoplasmic) were correlated to the secretion profile of malignant cells, patient outcomes and the presence of infiltrating immune cells within tumor microenvironment. Using several orthotopic, syngeneic mouse models of basal-like breast (4T1, 67NR and EpRas) or non-small cell lung (TC-1) cancer, the efficacy of several HMGB1 inhibitors alone and in combination with immune checkpoint blockade antibodies (anti-PD-1/PD-L1) was then investigated. Isolated from retrieved tumors, 14 immune cell (sub)populations as well as the activation status of antigen-presenting cells were extensively analyzed in each condition. Finally, the redox state of HMGB1 in tumor-extruded fluids and the influence of different forms (oxidized, reduced or disulfide) on both dendritic cell (DC) and plasmacytoid DC (pDC) activation were determined. Results Associated with an unfavorable prognosis in human patients, we clearly demonstrated that targeting extracellular HMGB1 elicits a profound remodeling of tumor immune microenvironment for efficient cancer therapy. Indeed, without affecting the global number of (CD45 + ) immune cells, drastic reductions of monocytic/granulocytic myeloid-derived suppressor cells (MDSC) and regulatory T lymphocytes, a higher M1/M2 ratio of macrophages as well as an increased activation of both DC and pDC were continually observed following HMGB1 inhibition. Moreover, blocking HMGB1 improved the efficacy of anti-PD-1 cancer monoimmunotherapy. We also reported that a significant fraction of HMGB1 encountered within cancer microenvironment (interstitial fluids) is oxidized and, in opposite to its reduced isoform, oxidized HMGB1 acts as a tolerogenic signal in a receptor for advanced glycation endproducts-dependent manner. Conclusion Collectively, we present evidence that extracellular HMGB1 blockade may complement first-generation cancer immunotherapies by remobilizing antitumor immune response.

Growth Suppression and Radiosensitivity Increase by HMGB1 in Breast Cancer

High-Mobility Group Boxes Mediate Cell Proliferation and Radiosensitivity Via Retinoblastoma-Interaction-Dependent and -Independent Mechanisms

HMGB1 increases radiosensitivity by interacting with HDAC1

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

Downregulation of High Mobility Group Box 1 Modulates Telomere Homeostasis and Increases the Radiosensitivity of Human Breast Cancer Cells.

The Effect of HMGB1 on the Clinicopathological and Prognostic Features of Cervical Cancer.

The mechanism of high mobility group box-1 protein and its bidirectional regulation in tumors

Multiple functions of HMGB1 in cancer

HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma

Targeting HMGB1: an Available Therapeutic Strategy for Breast Cancer Therapy

Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review)

Downregulation of High Mobility Group Box 1 Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Acting As a Crucial Target of Microrna-107

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy

HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer

The Dual Role and Therapeutic Potential of High-Mobility Group Box 1 in Cancer

HMGB3 Small Interfere RNA Suppresses Mammosphere Formation of MDA-MB-231 Cells by Down-Regulating Expression of HIF1α.

Exogenous HMGB1 Promoted Migration and Invasion of Breast Cancer Cells Through NFκB and MMP9

High Mobility Group Box-1 Inhibits Cancer Cell Motility and Metastasis by Suppressing Activation of Transcription Factor CREB and Nwasp Expression.

The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis

Bmi-1 Induces Radioresistance in MCF-7 Mammary Carcinoma Cells.